SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Amrutanjan Health Care shines on reporting 35.11% rise in Q3 net profit

13 Mar 2012 Evaluate

Amrutanjan Health Care is currently trading at Rs. 783.30, up by 11.40 points or 1.48% from its previous closing of Rs. 771.90 on the BSE.

The scrip opened at Rs. 779.85 and has touched a high and low of Rs. 804.85 and Rs. 777.05 respectively. So far 26,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 996.80 on 25-Jul-2011 and a 52 week low of Rs. 610.00 on 15-Mar-2011.

Last one week high and low of the scrip stood at Rs. 804.85 and Rs. 738.50 respectively. The current market cap of the company is Rs. 250.00 crore.

The promoters holding in the company stood at 50.71% while Institutions and Non-Institutions held 0.16% and 49.13% respectively.

The company has posted a rise of 35.11% in its net profit at Rs 4.31 crore for the quarter ended December 31, 2011 as compared to Rs 3.19 crore for the same quarter in the previous year. Total income has increased by 6.25% at Rs 36.36 crore for the quarter under review as compared to Rs 34.22 crore in the same quarter of 2010.

Amrutanjan Health Care has a wide range of ayurvedic and allopathic products. The company has diversified into various businesses in the health care segment like the Fine Chemical Division and Osmosys Medical Clinic located in Chennai. The company is also planning to consolidate its flagship product category - pain management - to compete with multinational brands such as GSK (Iodex), P&G (Vicks) and Reckitt Benckiser (Moov), more vigorously.

Amrutanjan Healthcar Share Price

546.50 7.85 (1.46%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×